05:55 PM EST, 02/05/2025 (MT Newswires) -- Kezar Life Sciences ( KZR ) filed a shelf registration statement with the US Securities and Exchange Commission Wednesday covering the potential sale of up to $400 million of securities from time to time in one or more offerings.

The statement covers common and preferred stock, debt securities, and warrants.

The company said it plans to use any net proceeds generated from the securities sale for working capital and general corporate purposes.

Kezar shares were down 2.7% in after-hours activity.